Left Ventricular Hypertrophy Among Chronic Kidney Disease Patients in Assiut University Hospital
1 other identifier
observational
200
0 countries
N/A
Brief Summary
Assess the prevalence and features of left ventricular hypertrophy in patients with chronic kidney disease (CKD) taking into account gender differences and stage of CKD. To detect factors those predict LVH in CKD. \*to assess the right ventricle dysfunction in CKD .
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Feb 2022
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 24, 2021
CompletedFirst Posted
Study publicly available on registry
August 12, 2021
CompletedStudy Start
First participant enrolled
February 1, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2022
CompletedFebruary 22, 2022
February 1, 2022
9 months
July 24, 2021
February 18, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
Detecting the prevalence of LVH in CKD.
The types of LVH in different stages of CKD. Risk factors of LVH in different stages of CKD
through study completion, an average of 1 year".
Secondary Outcomes (1)
The types of LVH in different stages of CKD. Risk factors of LVH in different stages of CKD
through study completion, an average of 1 year".
Interventions
Measure the Left ventricle (LV): IVS (interventricular septum), LVEDD(left ventricle end diastolic dimension ),LVESD((left ventricle end systolic dimension ), PWD(posterior wall dimension), LV systolic dysfunction and LV diastolic dysfunction.
Eligibility Criteria
Assess the prevalence and features of left ventricular hypertrophy in patients with chronic kidney disease (CKD) taking into account gender differences and stage of CKD.
You may qualify if:
- \- Patients with chronic renal disease (CKD) aged between 16 and 65 years will be included.
- CKD are diagnosed based on criteria proposed by KDIGO (Kidney Disease: Improving Global Outcomes) in 2002
You may not qualify if:
- Patients with structural heart disease (congenital or valvular heart disease). Patients with primary hypertension. Patients with obstructive or restrictive lung disease.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (1)
Vallianou NG, Mitesh S, Gkogkou A, Geladari E. Chronic Kidney Disease and Cardiovascular Disease: Is there Any Relationship? Curr Cardiol Rev. 2019;15(1):55-63. doi: 10.2174/1573403X14666180711124825.
PMID: 29992892BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Official title resident Doctor
Study Record Dates
First Submitted
July 24, 2021
First Posted
August 12, 2021
Study Start
February 1, 2022
Primary Completion
November 1, 2022
Study Completion
December 1, 2022
Last Updated
February 22, 2022
Record last verified: 2022-02